BHC
Bausch Health Companies Inc. NYSE Listed Mar 29, 1994$5.72
Mkt Cap $2.1B
52w Low $4.41
30.7% of range
52w High $8.69
50d MA $5.48
200d MA $6.36
P/E (TTM)
13.8x
EV/EBITDA
7.3x
P/B
5.6x
Debt/Equity
-38.4x
ROE
-28.3%
P/FCF
2.6x
RSI (14)
—
ATR (14)
—
Beta
0.40
50d MA
$5.48
200d MA
$6.36
Avg Volume
1.9M
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
2150 St. ElzEar Boulevard West · Laval, QC H7L 4A8 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | AMC | 0.81 | 0.78 | -3.7% | 5.59 | +4.7% | +2.3% | -1.2% | -2.1% | +2.0% | +0.2% | — |
| Feb 18, 2026 | AMC | 1.21 | 1.08 | -10.7% | 6.19 | -7.8% | -4.2% | +3.4% | -2.4% | +0.7% | +1.5% | — |
| Oct 29, 2025 | AMC | 1.07 | 1.16 | +8.4% | 5.90 | +6.8% | +12.0% | +6.2% | -3.0% | -1.0% | +0.6% | — |
| Jul 30, 2025 | AMC | 0.97 | 0.90 | -7.2% | 6.39 | -9.7% | -7.8% | -3.1% | +1.2% | +2.8% | -3.0% | — |
| Apr 30, 2025 | AMC | 0.83 | 0.59 | -28.9% | 5.30 | -1.9% | +0.0% | +2.3% | -9.0% | -3.9% | -0.8% | — |
| Feb 19, 2025 | AMC | 1.65 | 1.15 | -30.3% | 6.51 | +6.9% | +10.3% | +1.8% | -1.9% | +5.2% | +2.1% | — |
| Oct 30, 2024 | AMC | 1.03 | 1.12 | +8.7% | 8.17 | +3.7% | +12.6% | +6.3% | -5.3% | +4.6% | -2.0% | — |
| Aug 1, 2024 | AMC | 0.88 | 0.89 | +1.1% | 6.10 | -10.7% | -7.7% | -7.1% | +3.1% | -3.2% | +5.0% | — |
| May 2, 2024 | AMC | 0.75 | 0.59 | -21.3% | 8.09 | +0.1% | -3.3% | -3.8% | -1.5% | -5.1% | -1.1% | — |
| Feb 22, 2024 | AMC | 1.01 | 1.15 | +13.9% | 9.30 | +0.5% | -1.3% | -2.1% | +2.1% | +0.2% | +2.1% | — |
| Nov 2, 2023 | AMC | 0.92 | 1.03 | +12.0% | 7.34 | +1.1% | +3.1% | -1.6% | -2.7% | -1.1% | -4.6% | — |
| Aug 3, 2023 | AMC | 0.75 | 0.81 | +8.0% | 9.41 | +1.2% | -3.7% | -2.5% | +0.8% | -3.1% | -2.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $5.63 | $5.62 | -0.2% | -0.9% | +1.6% | -1.4% | +2.3% | -1.2% |
| Feb 25 | Barclays | Maintains | Equal Weight → Equal Weight | — | $6.02 | $6.10 | +1.3% | +1.5% | -1.1% | -1.8% | +0.3% | -3.7% |
| Jan 7 | Truist | Maintains | Hold → Hold | — | $7.63 | $7.71 | +1.0% | +3.5% | -1.6% | -4.6% | +1.1% | +0.1% |
| May 2 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $5.30 | $5.42 | +2.3% | +2.3% | -9.0% | -3.9% | -0.8% | +0.0% |
| Feb 6 | Jefferies | Downgrade | Buy → Hold | — | $7.34 | $7.30 | -0.5% | -10.9% | -1.4% | -2.0% | +0.8% | -0.2% |
| Jan 30 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $7.47 | $7.50 | +0.4% | -0.1% | -0.4% | -2.0% | -0.3% | +1.1% |
| Nov 1 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $9.20 | $9.31 | +1.2% | +6.3% | -5.3% | +4.6% | -2.0% | -0.8% |
| Aug 2 | Piper Sandler | Downgrade | Neutral → Underweight | — | $6.10 | $5.45 | -10.7% | -7.7% | -7.1% | +3.1% | -3.2% | +5.0% |
| Aug 2 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $6.10 | $5.45 | -10.7% | -7.7% | -7.1% | +3.1% | -3.2% | +5.0% |
| Jul 25 | Truist | Maintains | Hold → Hold | — | $5.81 | $5.77 | -0.7% | +1.2% | +1.9% | -0.7% | +0.2% | +1.2% |
| Apr 23 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $8.45 | $8.50 | +0.6% | +0.9% | +0.4% | +0.7% | +1.0% | +2.0% |
| Apr 12 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $8.97 | $8.84 | -1.4% | -2.3% | -1.5% | +1.3% | -0.9% | -0.7% |
| Apr 5 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $10.05 | $10.07 | +0.2% | +3.6% | -6.9% | -4.4% | -3.7% | +0.6% |
| Feb 23 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $9.30 | $9.35 | +0.5% | -1.3% | -2.1% | +2.1% | +0.2% | +2.1% |
| Sep 20 | Jefferies | Upgrade | Hold → Buy | — | $7.72 | $8.68 | +12.4% | +8.0% | +0.6% | -2.0% | +0.4% | -0.2% |
| Jun 16 | TD Cowen | Downgrade | Outperform → Market Perform | — | $7.44 | $7.24 | -2.7% | -1.2% | +0.7% | -0.4% | -0.5% | -1.9% |
| May 22 | Jefferies | Maintains | Buy → Buy | — | $8.30 | $8.46 | +1.9% | +6.0% | -4.4% | -1.5% | -1.0% | -0.7% |
| May 5 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $5.89 | $5.96 | +1.2% | -1.0% | +2.7% | -2.2% | +1.5% | -2.2% |
| Sep 9 | Piper Sandler | Maintains | Neutral → Neutral | — | $6.70 | $6.71 | +0.1% | +10.4% | -1.9% | +1.4% | +6.7% | -2.7% |
| Sep 1 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $5.97 | $5.76 | -3.5% | +10.4% | -2.1% | +0.6% | +7.1% | -3.6% |
| Aug 10 | BMO Capital | Maintains | Market Perform → Market Perform | — | $5.18 | $5.32 | +2.7% | +9.1% | +9.7% | -3.1% | +4.5% | +1.3% |
| Aug 10 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $5.18 | $5.32 | +2.7% | +9.1% | +9.7% | -3.1% | +4.5% | +1.3% |
| Jul 29 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $5.10 | $5.11 | +0.2% | -9.4% | -0.6% | -0.2% | +13.5% | -1.5% |
| Jul 29 | Truist | Downgrade | Buy → Hold | — | $5.10 | $5.11 | +0.2% | -9.4% | -0.6% | -0.2% | +13.5% | -1.5% |
| Jul 29 | JP Morgan | Downgrade | Overweight → Neutral | — | $5.10 | $5.11 | +0.2% | -9.4% | -0.6% | -0.2% | +13.5% | -1.5% |
| Jul 26 | RBC Capital | Maintains | Outperform → Outperform | — | $8.84 | $8.76 | -0.9% | -1.1% | -0.7% | -41.2% | -9.4% | -0.6% |
| May 13 | RBC Capital | Maintains | Outperform → Outperform | — | $10.45 | $10.53 | +0.8% | +3.7% | -0.6% | +2.4% | -9.8% | +2.0% |
| May 9 | RBC Capital | Maintains | Outperform → Outperform | — | $16.04 | $15.68 | -2.2% | -19.6% | -27.1% | +7.8% | +3.2% | +3.7% |
| Nov 3 | RBC Capital | Maintains | Outperform → Outperform | — | $25.87 | $25.98 | +0.4% | +5.3% | -0.7% | +3.4% | +0.9% | -2.5% |
| Oct 1 | Jefferies | Maintains | Buy → Buy | — | $27.85 | $27.94 | +0.3% | +2.7% | -2.1% | +0.4% | -1.8% | +1.2% |
| Jun 3 | Jefferies | Maintains | Buy → Buy | — | $31.89 | $31.80 | -0.3% | -0.6% | -1.1% | +0.9% | -1.1% | -0.1% |
| Mar 24 | BofA Securities | Downgrade | Neutral → Underperform | — | $31.66 | $30.55 | -3.5% | -3.0% | +1.3% | -0.3% | -1.0% | +1.1% |
| Mar 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.80 | $34.01 | +0.6% | -1.2% | -0.2% | -1.4% | +0.5% | -0.1% |
| Feb 26 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $31.28 | $31.42 | +0.4% | +0.4% | +1.1% | +1.7% | +0.9% | -2.0% |
| Feb 17 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $31.32 | $32.00 | +2.2% | +2.3% | -1.4% | +1.1% | -0.9% | -0.2% |
| Jan 15 | Jefferies | Maintains | Buy → Buy | — | $26.41 | $26.18 | -0.9% | -0.2% | +4.4% | -1.9% | -1.2% | -0.1% |
| Nov 25 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $19.24 | $19.08 | -0.8% | -0.4% | +1.9% | -4.9% | +0.4% | +2.2% |
| Nov 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.81 | $17.05 | +1.4% | -0.5% | -0.5% | +15.1% | +1.7% | -0.4% |
| Oct 28 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $17.74 | $17.26 | -2.7% | -5.5% | +0.5% | -2.1% | +5.1% | -6.1% |
| Sep 17 | BofA Securities | Upgrade | Underperform → Neutral | — | $16.88 | $16.94 | +0.4% | +3.0% | -1.1% | -3.9% | -2.9% | -1.9% |
| Aug 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.39 | $16.74 | +2.1% | +3.4% | +0.0% | +1.8% | -1.5% | -0.5% |
| Aug 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $17.33 | $17.23 | -0.6% | -2.7% | +0.1% | -2.9% | +3.4% | +0.0% |
| Aug 10 | Citigroup | Maintains | Buy → Buy | — | $18.05 | $18.33 | +1.6% | -1.8% | -0.3% | -1.5% | -1.2% | +1.7% |
| Jul 7 | BofA Securities | Maintains | Underperform → Underperform | — | $19.00 | $18.71 | -1.5% | -3.0% | -4.8% | -2.3% | +0.2% | +1.3% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.38 | $20.00 | +3.2% | +2.2% | +1.4% | -2.4% | +0.3% | -0.3% |
| May 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $15.87 | $15.81 | -0.4% | +5.9% | +0.4% | +1.7% | -4.6% | -2.6% |
| May 8 | CFRA | Maintains | Hold → Hold | — | $15.87 | $15.81 | -0.4% | +5.9% | +0.4% | +1.7% | -4.6% | -2.6% |
| May 8 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $15.87 | $15.81 | -0.4% | +5.9% | +0.4% | +1.7% | -4.6% | -2.6% |
| Apr 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $18.39 | $18.15 | -1.3% | -1.5% | -5.3% | -2.8% | +0.6% | +2.0% |
| Apr 28 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $18.11 | $18.65 | +3.0% | -3.3% | +5.0% | -1.5% | -5.3% | -2.8% |
No insider trades available.
8-K · 5.02
!!! Very High
Bausch Health Companies Inc -- 8-K 5.02: Executive Change
Bausch Health amended an executive's 2023 performance stock unit award, affecting 1.14 million PSUs originally scheduled to vest in March 2026, likely reflecting recent leadership changes or compensation restructuring.
Mar 2
8-K
Bausch Health Companies Inc -- 8-K Filing
Bausch Health Companies achieved eleven consecutive quarters of year-over-year revenue and adjusted EBITDA growth excluding Bausch + Lomb, demonstrating sustained operational improvement for investors.
Feb 18
Data updated apr 24, 2026 9:30pm
· Source: massive.com